| 王莲莲,马丽莉.达格列净联合沙库巴曲缬沙坦治疗老年急性心肌梗死后心衰的疗效及对Galectin-3、TMAO、CRP、BNP水平的影响.[J].中南医学科学杂志.,2023,(6):868-871. |
| 达格列净联合沙库巴曲缬沙坦治疗老年急性心肌梗死后心衰的疗效及对Galectin-3、TMAO、CRP、BNP水平的影响 |
| The therapeutic effect of dapagliflozin combined with shakubaqu valsartan in the treatment of heart failure after acute myocardial infarction in the elderly and its impact on Galectin-3, TMAO, CRP, BNP levels |
| 投稿时间：2022-11-03 修订日期：2023-09-21 |
| DOI：10.15972/j.cnki.43-1509/r.2023.06.015 |
| 中文关键词: 达格列净 沙库巴曲缬沙坦 心衰 急性心肌梗死 [ |
| 英文关键词:dapagliflozin shakubaqu valsartan heart failure acute myocardial infarction |
| 基金项目:国家重点研发计划“中医药现代化研究”专项课题(2017YFC1700503) |
|
| 摘要点击次数: 191 |
| 全文下载次数: 121 |
| 中文摘要: |
| 目的研究达格列净联合沙库巴曲缬沙坦治疗老年急性心肌梗死后心衰的疗效及对半乳糖凝集素-3(Galectin-3)、氧化三甲胺(TMAO)、C反应蛋白(CRP)、脑钠肽(BNP)水平的影响。 方法回顾性分析100例老年急性心肌梗死后心衰患者的临床资料,根据不同治疗方法分为对照组(沙库巴曲缬沙坦治疗)和观察组(达格列净联合沙库巴曲缬沙坦治疗)。比较两组临床疗效、Galectin-3、CRP、BNP、白细胞介素-6(IL-6)、TMAO、肿瘤坏死因子-α(TNF-α)、心功能、心室重塑指标以及药物不良事件发生率。 结果观察组总有效率高于对照组,不良反应发生率低于对照组(P＜0.05)。治疗6个月后,两组IL-6、Galectin-3、CRP、BNP、TMAO、TNF-α、左心室收缩期末内径、左心室质量指数、左心室舒张期末内径低于治疗前,左室射血分数、左心室重构指数高于治疗前；且观察组较对照组变化更显著(P＜0.05)。 结论达格列净联合沙库巴曲缬沙坦治疗老年心肌梗死后心力衰竭患者,可有效改善心功能和心室重塑,且药物不良反应小。 |
| 英文摘要: |
| AimTo study the therapeutic effect of dapagliflozin combined with shakubaqu valsartan in the treatment of heart failure after acute myocardial infarction in the elderly and its impact on the levels of galactin-3, trimethylamine oxide (TMAO), C-reactive protein (CRP), and brain natriuretic peptide (BNP). MethodsA retrospective analysis was conducted on the clinical data of 100 elderly patients with heart failure after acute myocardial infarction. They were divided into a control group (treated with shakubaqu valsartan) and an observation group (treated with dapagliflozin combined with shakubaqu valsartan) based on different treatment methods. The clinical efficacy, Galectin-3, CRP, BNP, IL-6, TMAO, tumor necrosis factor-α (TNF-α), cardiac function, ventricular remodeling indicators, and incidence of adverse drug events between two groups were compared. ResultsThe total effective rate of the observation group was higher than that of the control group, and the incidence of adverse reactions was lower than that of the control group (P＜0.05). After 6 months of treatment, IL-6, Galectin-3, CRP, BNP, TMAO, TNF-α levels, the left ventricular end systolic diameter, left ventricular mass index, and left ventricular end diastolic diameter in these two groups were lower than those before treatment, while the left ventricular ejection fraction and left ventricular remodeling index were higher than those before treatment. Furthermore,the observation group showed more significant changes compared with the control group (P＜0.05). ConclusionThe treatment with dapagliflozin combined with shakubaqu valsartan elderly patients with heart failure after myocardial infarction can effectively improve cardiac function and ventricular remodeling, with minimal adverse drug reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|